Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

Harbour BioMed, a global biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application (BLA) for batoclimab in the treatment of generalized myasthenia gravis (gMG). This marks the first BLA accepted by NMPA since Harbour BioMed's establishment. Batoclimab is an innovative therapy targeting anti-FcRn treat..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer

PDS Biotechnology has achieved the efficacy threshold in Stage 2 of the VERSATILE-002 trial with PDS0101 and KEYTRUDA® for head and neck cancer. The trial evaluates PDS0101, an HPV-targeted immunotherapy, combined with Merck’s anti-PD-1 therapy for the treatment of unresectable, recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer. Fourteen patients in the immune ch..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms